We use PASylation® — a powerful approach to design synthetic drugs with fine-tuned pharmacologic and pharmacokinetic properties to create promising disease-modifying therapies
We use PASylation® chemistry to develop long-acting analogs of naturally occurring hormones through the development of proprietary peptides, creating new molecular entities with optimized pharmacology and pharmacokinetics that maintains both the peptide's natural safety profile and increases the peptide's half-life, potency and efficacy
AntliaBio’s success is rooted in two key strategies and based on synthetic chemistry:
Once synthesized, we use a unique chemistry technique called PASylation® , which offers a simple and efficient manufacturing process and provides superior pharmacological properties to other polymer chemistry techniques
PASylation is the genetic fusion with conformationally disordered polypeptide sequences composed of the amino acids Pro, Ala, and/or Ser (‘PASylation’). PASylation provides a simple way to attach a solvated random chain with large hydrodynamic volume to the protein of biopharmaceutical interest. This amino acid string adopts a bulky random coil structure, which significantly increases the size of the resulting fusion protein. By this means the typically rapid clearance of the biologically active component via kidney filtration is retarded by 1-2 orders of magnitude.
Most of the commercially successful first-generation biopharmaceuticals are small proteins or peptides that suffer from rapid renal clearance, leading to disappointingly short circulation times limiting their potential therapeutic benefit. Compared with other strategies to prolong the plasma half-life of biopharmaceuticals (e.g., PEGylation through chemical conjugation with polyethylene glycol) PASylation ® technology provides significant immunogenic, manufacturing and storage advantages.
XL-protein’s proprietary PASylation® technology also provides for a strong patent protection. It is patented worldwide by two patent families, including patents issued in Europe, the United States, Japan as well as several other countries and territories.
XL-protein® and PASylation® are registered trademarks of XL-protein GmbH.
Copyright © 2021 Antlia Bioscience, Inc. - All Rights Reserved.